Health Care • Biotechnology: Pharmaceutical Preparations
$149.52 ▲ +3.19
(+2.18%)
MKT CAP: $361.02B • VOL: 12.35M
52W L $82 52W H $157
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$126
MEDIAN
$167
MEAN
$170
HIGH
$203
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MRK TAPE
MRK // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $180.92 | $171.95 | 2025-02-14 | $136.06 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $188.40 | $176.43 | 2025-02-06 | $140.55 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $170.45 | $164.47 | 2025-01-29 | $143.54 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $152.51 | — | 2025-01-17 | $146.53 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $131.58 | $142.04 | 2025-01-09 | $133.07 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $177.93 | $155.50 | 2024-12-18 | $130.08 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $145.03 | $151.02 | 2024-12-04 | $139.05 | -4.3% | 48% | C |